Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma

Alison J. Moskowitz, Miguel Angel Perales, Tarun Kewalramani, Joachim Yahalom, Hugo Castro-Malaspina, Zhigang Zhang, Jill Vanak, Andrew D. Zelenetz, Craig Moskowitz

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

Most patients with Hodgkin lymphoma (HL) are cured with first and second-line treatment; however, the outcome is unknown for those who fail high dose chemoradiotherapy with autologous stem cell transplant (HDT-ASCT). This report is an analysis of patients with relapsed and primary refractory HL who were treated with HDT-ASCT and failed due to progression of disease (POD). Two hundred and two patients received HDT-ASCT at Memorial Sloan Kettering Cancer Center for relapsed or refractory HL between December 1994 and 2005 and 71 failed due to POD. The median survival following HDT-ASCT failure was 25 months. Only 16 (23%) of the 71 patients are currently alive, nine of whom are in remission. Multivariate analysis revealed two factors associated with poor outcome: relapse within 6 months of HDT-ASCT and primary refractory disease. The only factor associated with improved survival was the ability to receive a second transplant, in particular, reduced intensity allogeneic transplant (RIT). Novel therapies are needed for patients who fail HDT-ASCT, particularly those with primary refractory disease and those who relapse within 6 months of HDT-ASCT. Future studies should focus on prospectively evaluating RIT following HDT-ASCT failure in patients with remission duration from HDT-ASCT of >6 months.

Original languageEnglish (US)
Pages (from-to)158-163
Number of pages6
JournalBritish Journal of Haematology
Volume146
Issue number2
DOIs
StatePublished - Jul 1 2009
Externally publishedYes

Fingerprint

Chemoradiotherapy
Hodgkin Disease
Stem Cells
Transplants
Disease Progression
Recurrence
Survival
Multivariate Analysis

Keywords

  • Autologous stem cell transplant
  • Hodgkins lymphoma
  • Reduced intensity transplant
  • Relapse
  • Transplantation

ASJC Scopus subject areas

  • Hematology

Cite this

Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. / Moskowitz, Alison J.; Perales, Miguel Angel; Kewalramani, Tarun; Yahalom, Joachim; Castro-Malaspina, Hugo; Zhang, Zhigang; Vanak, Jill; Zelenetz, Andrew D.; Moskowitz, Craig.

In: British Journal of Haematology, Vol. 146, No. 2, 01.07.2009, p. 158-163.

Research output: Contribution to journalArticle

Moskowitz, Alison J. ; Perales, Miguel Angel ; Kewalramani, Tarun ; Yahalom, Joachim ; Castro-Malaspina, Hugo ; Zhang, Zhigang ; Vanak, Jill ; Zelenetz, Andrew D. ; Moskowitz, Craig. / Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma. In: British Journal of Haematology. 2009 ; Vol. 146, No. 2. pp. 158-163.
@article{44c7d9ae4f51438592ec27fb20ee0d69,
title = "Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma",
abstract = "Most patients with Hodgkin lymphoma (HL) are cured with first and second-line treatment; however, the outcome is unknown for those who fail high dose chemoradiotherapy with autologous stem cell transplant (HDT-ASCT). This report is an analysis of patients with relapsed and primary refractory HL who were treated with HDT-ASCT and failed due to progression of disease (POD). Two hundred and two patients received HDT-ASCT at Memorial Sloan Kettering Cancer Center for relapsed or refractory HL between December 1994 and 2005 and 71 failed due to POD. The median survival following HDT-ASCT failure was 25 months. Only 16 (23{\%}) of the 71 patients are currently alive, nine of whom are in remission. Multivariate analysis revealed two factors associated with poor outcome: relapse within 6 months of HDT-ASCT and primary refractory disease. The only factor associated with improved survival was the ability to receive a second transplant, in particular, reduced intensity allogeneic transplant (RIT). Novel therapies are needed for patients who fail HDT-ASCT, particularly those with primary refractory disease and those who relapse within 6 months of HDT-ASCT. Future studies should focus on prospectively evaluating RIT following HDT-ASCT failure in patients with remission duration from HDT-ASCT of >6 months.",
keywords = "Autologous stem cell transplant, Hodgkins lymphoma, Reduced intensity transplant, Relapse, Transplantation",
author = "Moskowitz, {Alison J.} and Perales, {Miguel Angel} and Tarun Kewalramani and Joachim Yahalom and Hugo Castro-Malaspina and Zhigang Zhang and Jill Vanak and Zelenetz, {Andrew D.} and Craig Moskowitz",
year = "2009",
month = "7",
day = "1",
doi = "10.1111/j.1365-2141.2009.07727.x",
language = "English (US)",
volume = "146",
pages = "158--163",
journal = "British Journal of Haematology",
issn = "0007-1048",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Outcomes for patients who fail high dose chemoradiotherapy and autologous stem cell rescue for relapsed and primary refractory Hodgkin lymphoma

AU - Moskowitz, Alison J.

AU - Perales, Miguel Angel

AU - Kewalramani, Tarun

AU - Yahalom, Joachim

AU - Castro-Malaspina, Hugo

AU - Zhang, Zhigang

AU - Vanak, Jill

AU - Zelenetz, Andrew D.

AU - Moskowitz, Craig

PY - 2009/7/1

Y1 - 2009/7/1

N2 - Most patients with Hodgkin lymphoma (HL) are cured with first and second-line treatment; however, the outcome is unknown for those who fail high dose chemoradiotherapy with autologous stem cell transplant (HDT-ASCT). This report is an analysis of patients with relapsed and primary refractory HL who were treated with HDT-ASCT and failed due to progression of disease (POD). Two hundred and two patients received HDT-ASCT at Memorial Sloan Kettering Cancer Center for relapsed or refractory HL between December 1994 and 2005 and 71 failed due to POD. The median survival following HDT-ASCT failure was 25 months. Only 16 (23%) of the 71 patients are currently alive, nine of whom are in remission. Multivariate analysis revealed two factors associated with poor outcome: relapse within 6 months of HDT-ASCT and primary refractory disease. The only factor associated with improved survival was the ability to receive a second transplant, in particular, reduced intensity allogeneic transplant (RIT). Novel therapies are needed for patients who fail HDT-ASCT, particularly those with primary refractory disease and those who relapse within 6 months of HDT-ASCT. Future studies should focus on prospectively evaluating RIT following HDT-ASCT failure in patients with remission duration from HDT-ASCT of >6 months.

AB - Most patients with Hodgkin lymphoma (HL) are cured with first and second-line treatment; however, the outcome is unknown for those who fail high dose chemoradiotherapy with autologous stem cell transplant (HDT-ASCT). This report is an analysis of patients with relapsed and primary refractory HL who were treated with HDT-ASCT and failed due to progression of disease (POD). Two hundred and two patients received HDT-ASCT at Memorial Sloan Kettering Cancer Center for relapsed or refractory HL between December 1994 and 2005 and 71 failed due to POD. The median survival following HDT-ASCT failure was 25 months. Only 16 (23%) of the 71 patients are currently alive, nine of whom are in remission. Multivariate analysis revealed two factors associated with poor outcome: relapse within 6 months of HDT-ASCT and primary refractory disease. The only factor associated with improved survival was the ability to receive a second transplant, in particular, reduced intensity allogeneic transplant (RIT). Novel therapies are needed for patients who fail HDT-ASCT, particularly those with primary refractory disease and those who relapse within 6 months of HDT-ASCT. Future studies should focus on prospectively evaluating RIT following HDT-ASCT failure in patients with remission duration from HDT-ASCT of >6 months.

KW - Autologous stem cell transplant

KW - Hodgkins lymphoma

KW - Reduced intensity transplant

KW - Relapse

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=67649939212&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649939212&partnerID=8YFLogxK

U2 - 10.1111/j.1365-2141.2009.07727.x

DO - 10.1111/j.1365-2141.2009.07727.x

M3 - Article

VL - 146

SP - 158

EP - 163

JO - British Journal of Haematology

JF - British Journal of Haematology

SN - 0007-1048

IS - 2

ER -